143669-41-4

Usage

Uses

Used in Industrial Applications:
(1,4-dioxan-2-yl)methanol is used as a solvent for various industrial processes, serving as a cleaner for electronic components and aiding in the dissolution of cellulose acetate.
Used in Pharmaceutical Production:
In the pharmaceutical industry, (1,4-dioxan-2-yl)methanol is utilized in the production of various medications, playing a crucial role in the synthesis and formulation of drugs.
Used in Agricultural Chemicals:
(1,4-dioxan-2-yl)methanol also finds its application in the agricultural sector, where it is employed in the development of agricultural chemicals, contributing to crop protection and enhancement.
However, due to its hazardous nature, (1,4-dioxan-2-yl)methanol is regulated and requires careful handling. It has the potential to cause skin and eye irritation, and it can form explosive peroxides if exposed to air or light. Therefore, it is essential to follow proper safety protocols when working with this chemical compound.

Upstream product

• 5412-14-6 3-(β-Chloroethoxy)-1,2-epoxypropane 
• 143669-40-3 (+/-)-3,6,8-trioxabicyclo<3.2.1>octane 
• 16801-25-5 1-(2-hydroxyethoxy)-2,3-epoxypropane 
• 7664-93-9 sulfuric acid 
• 87179-37-1 (+/-)-2-(bromomethyl)-4-(hydroxymethyl)-1,3-dioxalane 
• 68391-40-2 acetoxymethyl-[1,4]dioxane 
• 406913-87-9 (1S,5R)-3,6,8-trioxabicyclo[3.2.1]octane 
• 406913-91-5 Phthalic acid mono-(S)-1-[1,4]dioxan-2-ylmethyl ester 
• 406913-89-1 Phthalic acid mono-(R)-1-[1,4]dioxan-2-ylmethyl ester 
• 861852-08-6 (2R)-2-[(2-chloroethoxy)methyl]oxirane 
• 99777-55-6 ethyl 2-(1,4-dioxan-2-ylmethoxy)crotonate 
• 51594-55-9 (R)-(-)-epichlorohydrin 
• 107-07-3 2-chloro-ethanol 
• 27905-76-6 2-(2-chloroethoxy)-3-chloropropan-2-ol 

Downstream Products

• 21048-16-8 2-(chloromethyl)-1,4-dioxane 
• 406913-88-0 (R)-(-)-2-hydroxymethyl-1,4-dioxane 
• 406913-93-7 [(2S)-1,4-dioxan-2-yl]methanol 
• 934346-74-4 (R)-1,4-dioxane-2-carboxaldehyde 
• 917882-66-7 N-((2R)-1,4-dioxan-2-ylmethyl)-N-methyl-N’-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]sulfamide 
• 1346262-49-4 (R)-2-{N-[((S)-1,4-dioxan-2-yl)methyl]-4-chlorophenylsulfonamido}-5,5,5-trifluoropentanamide 
• 1337470-52-6 (S)-(1,4-dioxan-2-yl)methanamine 
• 1569298-20-9 C₁₀H₁₉NO₄ 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of dioxane-based antiviral agents targeted against the Sindbis virus capsid protein

Dioxane-based antiviral agents targeted to the hydrophobic binding pocket of Sindbis virus capsid protein were designed by computer graphics molecular modeling and synthesized. Virus production using SIN-IRES-Luc and capsid assembly were monitored to eval

Meso-Tetra(dioxanyl)porphyrins: Neutral, low molecular weight, and chiral porphyrins with solubility in aqueous solutions

The synthesis of the low-molecular weight, meso-Tetra(dioxan-2-yl)porphyrin with considerable solubility in aqueous solution is described. The key intermediate dioxan-2-carbaldehyde is accessible in either racemic or in stereo-pure forms from commercially available starting materials in three steps. Using 4 × 1 or 2 + 2-Type syntheses provide the porphyrin in modest yields. While the racemic aldehyde created an intractable mixture of diastereomers, the enantiopure aldehyde created a single enantiomer of the target porphyrin. The porphyrin was spectroscopically characterized. As its free base or zinc complex, it showed excellent solubility properties in organic and aqueous solvents, though free water-solubility was not achieved. The work expands on the availability of chiral porphyrins and neutral porphyrins with considerable solubility in aqueous solution.

CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS

The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1 Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES

The present invention relates to lH-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for treating neoplastic, autoimmune or neurodegenerative diseases. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 162 to 233; examples 1 to 8; table; compound examples cpd-1 to cpd-135; biological examples 1 to 4).

HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR

A pro-apoptotic solid dispersion comprises, a Bcl -2 family protein inhibitory compound of Formula A as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier, and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula A, the water-soluble polymeric carrier, and the surfactant to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier, and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl -2 family proteins, for example cancer or an immune or autoimmune disease.

Method for Producing Diarylpyridine Derivatives

The present invention relates to a novel method for producing diarylpyridine derivatives, and the object of the present invention is to provide a novel, industrially useful method. The present inventors developed a novel method for synthesizing pyridine r

BCL-2 INHIBITORS

The disclosure includes compounds of Formula (A), (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1, Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

BCL-2 INHIBITORS

The disclosure includes compounds of Formula (I), (I) wherein Z, Q1, Q3, Q4, Q5, Q6, Q7, R0, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, g, k, m, n, s, v, j, L, Z1, and, W are defined herein. Also disclosed is a method for treating a neoplastic disease and autoimmune disease with these compounds.

1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES

The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS

Disclosed herein are protein kinase inhibitors, more particularly novel quinazoline derivatives and pharmaceutical compositions thereof,and method of use thereof.